As shown in Figures 1E,F, RA patients with moderate-to-severe NAFLD had significantly higher serum levels of Gal-9 and sTIM-3 (5.55 ng/mL, IQR 4.14–6.27 ng/mL; 5.04 ng/mL, IQR 3.44–6.48 ng/mL, respectively) than those with none-to-mild NAFLD (3.04 ng/mL, IQR 2.68–3.73 ng/mL, p < 0.001; 3.51 ng/mL, IQR 2.94–4.75 ng/mL, p < 0.05, respectively). This evidence concerns the gene LGALS9 and metabolic dysfunction-associated steatotic liver disease.